Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Combination therapy for the treatment of cancer
US9486471B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9486471-B2 |
| Application number | US-201414461783-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 18, 2014 |
| Priority date | Mar 28, 2012 |
| Publication date | Nov 8, 2016 |
| Grant date | Nov 8, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid leukemia.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating leukemia in a subject in need thereof comprising administering to the subject a conjugate comprising cytarabine and thioridazine. 2. The method of claim 1 , wherein the leukemia is acute myeloid leukemia (AML). 3. The method of claim 1 , wherein the subject is in remission. 4. The method of claim 1 , wherein the subject is a human. 5. The method of claim 1 , wherein cytarabine and thioridazine are conjugated through a linker. 6. A conjugate comprising cytarabine and thioridazine. 7. The conjugate of claim 6 , wherein cytarabine and thioridazine are conjugated through a linker. 8. The conjugate of claim 7 , wherein the linker comprises polyethylene glycol, polypropylene glycol, polyvinyl alcohol or polyvinylpyrrolidone. 9. The method of claim 5 , wherein the linker comprises polyethylene glycol, polypropylene glycol, polyvinyl alcohol or polyvinylpyrrolidone.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
specific for leukemia · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam · CPC title
having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9486471B2 cover?
- Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid …
- Who is the assignee on this patent?
- Univ Mcmaster
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7068. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).